SecBot SecBot

FDMT

4D Molecular Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001650648 Biotech & Drug Discovery
$11.03 +0.23 (+2.13%)
Oct 26 4:00 PM ET · prev $10.80
Market cap
$654.6M
Small cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
$28.00
+154% · range $18.00–37.00
Next earnings
Nov 11
in 15 days · EPS est. −$1.05
1 year
−10.1%
from $12.27 · Oct 27
30 days
−24.2%
from $14.56
52-week range
$7.19–16.76
−34% from high · low Jan 6
Avg volume 20D
1.05M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$5.3M
0 buyers · 3 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Two insiders at 4D Molecular Therapeutics sold a total of $833K in shares over a week, led by CEO David Kirn…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $5.3M.

  • InstitutionsBULLISH

    Q2 2026: 25 added (1 new), 9 trimmed or exited. Largest new: Vanguard Capital Management $27.9M.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.014 → −$1.050 over 90 days. 1 up, 1 down in 30 days.

  • TrendDOWNTREND

    21% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$27.9M
in new stakes
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD2,249,203$29.9M
VANGUARD CAPITAL MANAGEMENT LLCNEW2,099,055$27.9M
DIMENSIONAL FUND ADVISORS LPADD730,857$9.7M
CITADEL ADVISORS LLCDOUBLED687,597$9.1M
NORTHERN TRUST CORPADD562,929$7.5M
MORGAN STANLEYADD503,020$6.7M
Schonfeld Strategic Advisors LLCDOUBLED407,470$5.4M
UBS Group AGADD256,673$3.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy5Buy11Hold2Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +154%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 22, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 6, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 29, 2026B of A Securities
MAINTAIN
MAINTAINBuy
Sep 14, 2026Cantor Fitzgerald
UPGRADE
UPGRADEOverweight
Jul 31, 2026B. Riley Securities
INITIATE
INITIATEBuy
Jul 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$5.3M
sold · 3 insiders
DateInsiderTypeValue
Oct 16, 2026
Bizily Scott
Chief Legal Officer
EXERCISE$6.8K
Oct 16, 2026
Bizily Scott
Chief Legal Officer
SELL$21.0K
Oct 5, 2026
Kirn David
See Remarks
SELL$3.7K
Oct 5, 2026
Kirn David
See Remarks
SELL$750.2K
Sep 16, 2026
Bizily Scott
Chief Legal Officer
EXERCISE$6.8K
Sep 16, 2026
Bizily Scott
Chief Legal Officer
SELL$22.3K
Sep 14, 2026
Kirn David
See Remarks
SELL$811.0K
Sep 1, 2026
Bizily Scott
Chief Legal Officer
SELL$8.2K

Earnings setup

Estimates
Nov 11
reports in 15 days
−$1.05
EPS estimate, this quarter
−4%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.05-$1.10–-$0.99-0.9%$3.1M
Next Q-$1.06-$1.23–-$0.95-2.9%$3.9M
Current FY-$4.15-$4.30–-$4.00-0.4%$13.3M
Next FY-$4.09-$4.94–-$3.38-0.1%$20.6M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 Other
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT
Oct 16, 2026 Insider
Bizily Scott acquired via exercise 1,635 shares
Chief Legal Officer @ $4.14 ($6.8K)
Oct 16, 2026 Insider
Bizily Scott sold 1,635 shares
Chief Legal Officer @ $12.84 ($21.0K)
Oct 5, 2026 Insider
Kirn David sold 272 shares
See Remarks @ $13.61 ($3.7K)
Sep 22, 2026 SEC
Two insiders at 4D Molecular Therapeutics sold a total of $833K in shares over a week, led by CEO David Kirn with…
CLUSTER — Impact 4/10
Aug 21, 2026 SEC
CEO David Kirn and CLO Scott Bizily sold a combined ~$683K in open-market sales after exercising stock options. The…
CLUSTER — Impact 3/10
Jul 20, 2026 SEC
4D Molecular Therapeutics reported positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD, showing…
8-K — Impact 7/10
Jul 18, 2026 Press
4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD, showing…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
FDMT Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 16, 2026
Press release
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage…
Sep 28, 2026
Press release
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage…
Aug 25, 2026
Press release
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage…
Aug 14, 2026
Press release
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage…
Aug 10, 2026
Earnings date
FDMT Q2 2026 Earnings Scheduled — 2026-08-10

SecBot reports

7 filings · 2 press releases · 2 bullish · 1 bearish · 4 neutral
All FDMT filing & press-release reports (9)